Mesoblast resubmits biologic license application (bla) to fda for remestemcel-l in children with steroid-refractory acute graft versus host disease (sr-agvhd)

Validation of remestemcel-l potency assay used in the phase 3 trial which measures in-vivo activity based on mechanism of action

MESO Ratings Summary

MESO Quant Ranking